OBJECTIVES: We examined the utility of circulating total and IgG4+ plasmablasts as biomarkers of diagnosis and disease activity in IgG4-related disease (IgG4-RD). MATERIALS METHODS: We evaluated patients with active, untreated, biopsy-proven IgG4-RD affecting various organs. Flow cytometry was used to measure total plasmablast and IgG4+ plasmablast counts by gating peripheral blood for CD19lowCD38+CD20-CD27+ cells and CD19lowCD38+CD20-CD27+IgG4+ cells. Serum IgG4 concentrations were measured by nephelometry. We compared 37 IgG4-RD patients to 35 controls, including healthy individuals (n=14) and patients with other inflammatory diseases before treatment (n=21). RESULTS: The IgG4-RD patients' mean age was 59, and 68% were male. Fourteen patients (38%) had three or more organs involved. The IgG4-RD patients had substantially elevated total plasmablast counts (median 4698/mL, range 610-79524/mL) compared to both untreated disease controls (median 592/mL, range 19-4294/mL; p < 0.001) and healthy controls (median 94/mL, range 1-653/mL; p < 0.001). Thirteen IgG4-RD patients (36%) had normal serum IgG4 concentrations (mean 60 mg/dL, range 5-123 mg/dL, normal <135 mg/dL). However, the median plasmablast count was not significantly lower in that subset with normal serum IgG4 concentrations (3784/mL) compared to those with elevated serum IgG4 (5155/mL) (p = 0.242). Among the 12 rituximab (RTX)-treated patients, the median plasmablast level during disease flare was 6356/mL (range 1123-41589/mL), declining to 1419/mL (range 386/mL-4150/mL) during remission (p < 0.01). CONCLUSIONS: Circulating plasmablasts are elevated in active IgG4-RD, even in patients with normal serum IgG4 concentrations. Plasmablast counts are a potentially useful biomarker for diagnosis, assessing response to treatment, and determining the appropriate time for re-treatment. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVES: We examined the utility of circulating total and IgG4+ plasmablasts as biomarkers of diagnosis and disease activity in IgG4-related disease (IgG4-RD). MATERIALS METHODS: We evaluated patients with active, untreated, biopsy-proven IgG4-RD affecting various organs. Flow cytometry was used to measure total plasmablast and IgG4+ plasmablast counts by gating peripheral blood for CD19lowCD38+CD20-CD27+ cells and CD19lowCD38+CD20-CD27+IgG4+ cells. Serum IgG4 concentrations were measured by nephelometry. We compared 37 IgG4-RD patients to 35 controls, including healthy individuals (n=14) and patients with other inflammatory diseases before treatment (n=21). RESULTS: The IgG4-RD patients' mean age was 59, and 68% were male. Fourteen patients (38%) had three or more organs involved. The IgG4-RD patients had substantially elevated total plasmablast counts (median 4698/mL, range 610-79524/mL) compared to both untreated disease controls (median 592/mL, range 19-4294/mL; p < 0.001) and healthy controls (median 94/mL, range 1-653/mL; p < 0.001). Thirteen IgG4-RD patients (36%) had normal serum IgG4 concentrations (mean 60 mg/dL, range 5-123 mg/dL, normal <135 mg/dL). However, the median plasmablast count was not significantly lower in that subset with normal serum IgG4 concentrations (3784/mL) compared to those with elevated serum IgG4 (5155/mL) (p = 0.242). Among the 12 rituximab (RTX)-treated patients, the median plasmablast level during disease flare was 6356/mL (range 1123-41589/mL), declining to 1419/mL (range 386/mL-4150/mL) during remission (p < 0.01). CONCLUSIONS: Circulating plasmablasts are elevated in active IgG4-RD, even in patients with normal serum IgG4 concentrations. Plasmablast counts are a potentially useful biomarker for diagnosis, assessing response to treatment, and determining the appropriate time for re-treatment. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Kasia Owczarczyk; Preeti Lal; Alexander R Abbas; Kristen Wolslegel; Cecile T J Holweg; Wolfgang Dummer; Ariella Kelman; Paul Brunetta; Nicholas Lewin-Koh; Marco Sorani; Diane Leong; Paul Fielder; David Yocum; Carole Ho; Ward Ortmann; Michael J Townsend; Timothy W Behrens Journal: Sci Transl Med Date: 2011-09-21 Impact factor: 17.956
Authors: José Antonio Plaza; James A Garrity; Ahmet Dogan; Anuradha Ananthamurthy; Thomas E Witzig; Diva R Salomão Journal: Arch Ophthalmol Date: 2011-04
Authors: Arezou Khosroshahi; Lynn A Cheryk; Mollie N Carruthers; Judith A Edwards; Donald B Bloch; John H Stone Journal: Arthritis Rheumatol Date: 2014-01 Impact factor: 10.995
Authors: Edward M Vital; Shouvik Dass; Maya H Buch; Karen Henshaw; Colin T Pease; Michael F Martin; Frederique Ponchel; Andrew C Rawstron; Paul Emery Journal: Arthritis Rheum Date: 2011-10
Authors: Zachary S Wallace; Hamid Mattoo; Vinay S Mahajan; Maria Kulikova; Leo Lu; Vikram Deshpande; Hyon K Choi; Shiv Pillai; John H Stone Journal: Rheumatology (Oxford) Date: 2016-02-16 Impact factor: 7.580
Authors: Hang Liu; Cory A Perugino; Musie Ghebremichael; Zachary S Wallace; Sydney B Montesi; John H Stone; Shiv Pillai Journal: Arthritis Rheumatol Date: 2020-02-10 Impact factor: 10.995
Authors: Emanuel Della-Torre; Hamid Mattoo; Vinay S Mahajan; Vikram Deshpande; Donald Krause; Philip Song; Shiv Pillai; John H Stone Journal: Ann Rheum Dis Date: 2014-03-20 Impact factor: 19.103
Authors: Cory A Perugino; Sultan B AlSalem; Hamid Mattoo; Emanuel Della-Torre; Vinay Mahajan; Gayathri Ganesh; Hugues Allard-Chamard; Zachary Wallace; Sydney B Montesi; Johannes Kreuzer; Wilhelm Haas; John H Stone; Shiv Pillai Journal: J Allergy Clin Immunol Date: 2018-05-29 Impact factor: 10.793